Genentech
A Member of the Roche Group

August 28, 2020

Update: Court overturns US District Court decision, changing 'antibody' definition

On December 3, 2018 a US court issued a patent interpretation decision and agreed with Genentech on the definition of certain key terms related to Baxalta's patent – 'antibody' and 'antibody fragment'. It was based on these definitions of key terms that the US District Court issued a judgment that Hemlibra does not infringe Baxalta's patent.

We were disappointed to learn on August 27, 2020 that the US Federal Circuit Court of Appeals ruling reversed that judgment, which now returns the case to the US District Court for further proceedings. We do not know if or when a trial may take place or when the case may be resolved.

We take these allegations seriously and Genentech will continue to defend against them. We do not believe that the claims in this patent (US Patent, 7,033,590) are valid. This outcome does not affect the availability or supply of Hemlibra in the United States.

At the Roche Group – Genentech in the US, Chugai in Japan, and Roche in the rest of the world – we continue to focus on the hemophilia community and continuing our efforts to bring this prophylactic treatment option to people all over the world who are living with hemophilia A and may benefit from this therapy.

If you have any questions about this update, please do not hesitate to contact me.

Sincerely,

Gina Truslow
Sr. Manager, Patient Advocacy Relations - OMNI